BIOFILCHEM2026-01-012026-03-31BIOFILCHEM2026-03-31BIOFILCHEM2025-03-31BIOFILCHEM2025-04-012026-03-31BIOFILCHEM2026-01-012026-03-31in-capmkt:OtherExpenses1MemberBIOFILCHEM2026-01-012026-03-31in-capmkt:OtherExpenses2MemberBIOFILCHEM2026-01-012026-03-31in-capmkt:OtherExpenses3MemberBIOFILCHEM2025-04-012026-03-31in-capmkt:OtherExpenses1MemberBIOFILCHEM2025-04-012026-03-31in-capmkt:OtherExpenses2MemberBIOFILCHEM2025-04-012026-03-31in-capmkt:OtherExpenses3MemberBIOFILCHEM2026-03-31OtherNoncurrentAssetsDomain1BIOFILCHEM2026-03-31OtherCurrentAssetsDomain1BIOFILCHEM2026-03-31OtherCurrentAssetsDomain2BIOFILCHEM2026-03-31OtherCurrentAssetsDomain3BIOFILCHEM2026-03-31OtherCurrentAssetsDomain4BIOFILCHEM2026-03-31OtherCurrentLiabilitiesDomain1BIOFILCHEM2026-03-31OtherCurrentLiabilitiesDomain2BIOFILCHEM2026-01-012026-03-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2026-01-012026-03-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2025-04-012026-03-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-04-012026-03-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2026-01-012026-03-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2026-01-012026-03-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2025-04-012026-03-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-04-012026-03-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2026-01-012026-03-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2026-03-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2026-01-012026-03-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2026-03-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2026-01-012026-03-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2026-03-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2026-01-012026-03-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2026-03-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1BIOFILCHEM2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1BIOFILCHEM2026-01-012026-03-31RelatedPartyTransactionDomain1BIOFILCHEM2025-12-31RelatedPartyTransactionDomain1BIOFILCHEM2026-03-31RelatedPartyTransactionDomain1BIOFILCHEM2026-01-012026-03-31RelatedPartyTransactionDomain2BIOFILCHEM2025-12-31RelatedPartyTransactionDomain2BIOFILCHEM2026-03-31RelatedPartyTransactionDomain2BIOFILCHEM2026-01-012026-03-31RelatedPartyTransactionDomain3BIOFILCHEM2025-12-31RelatedPartyTransactionDomain3BIOFILCHEM2026-03-31RelatedPartyTransactionDomain3BIOFILCHEM2026-01-012026-03-31RelatedPartyTransactionDomain4BIOFILCHEM2025-12-31RelatedPartyTransactionDomain4BIOFILCHEM2026-03-31RelatedPartyTransactionDomain4BIOFILCHEM2026-01-012026-03-31RelatedPartyTransactionDomain5BIOFILCHEM2025-12-31RelatedPartyTransactionDomain5BIOFILCHEM2026-03-31RelatedPartyTransactionDomain5BIOFILCHEM2026-01-012026-03-31RelatedPartyTransactionDomain6BIOFILCHEM2025-12-31RelatedPartyTransactionDomain6BIOFILCHEM2026-03-31RelatedPartyTransactionDomain6BIOFILCHEM2026-01-012026-03-31RelatedPartyTransactionDomain7BIOFILCHEM2025-12-31RelatedPartyTransactionDomain7BIOFILCHEM2026-03-31RelatedPartyTransactionDomain7BIOFILCHEM2026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524396BIOFILCHEMNOTLISTEDINE829A01014BIOFIL CHEMICALS & PHARMACEUTICALS LIMITEDMain BoardEquity2025-04-012026-03-312026-05-302026-05-21INRLakhsQuarterlyFourth quarterMulti segment2026-05-3016:30:002026-05-3017:30:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-02-11https://mufmerinmovawwcvpkjx.supabase.co/storage/v1/object/public/investor_documents/investor_documents/Policy%20on%20dealing%20with%20related%20party%20transactions_11.02.2025.pdffalsefalseNot Applicable2026-01-012026-03-31AuditedStandalone75656000108500076741000179840001954300028296000220000020007410003287000720530004688000046880001000256500025660000212200000002122000-320002090000162738000100.130.13000.130.131.The above Audited Financial Results for the Quarter and financial year ended March 31, 2026 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on 30th May 2026. The above results have been audited by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs. <BR> <BR> 2.This statement has been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India (SEBI) and the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. <BR> <BR> 3.The figures for the quarter ended 31st March 2026 and 31st March 2025 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter. <BR> <BR> 4.The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments <BR> a. Pharma Division <BR> b. Chemicals Division <BR> <BR> 5. Statutory Auditors of the Company has carried out audit of the books of accounts for the financial year 2025-2026 and issued us an Audit Report with unmodified opinion on Audited Financial Year for the quarter/year ended on 31st March, 2026, therefore the Company is not required to give statement of impact of Audit Qualification for Audit Report with modified opinion. <BR> <BR> 6.The aforesaid audited financial Results will be uploaded on the Company’s website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors. Further Publication containing a Quick Response Code and the details of the web page where complete financial results of the company are available will be published in english and hindi. <BR> <BR> 7.The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary. <BR> <BR> 8. The Statement of Assets & Liabilities as at March 31, 2026 is annexed with the results along with the Statement of Cash Flow. <BR> <BR> 9.The Net Profit of the company for the year ended 31st March, 2026 has been increased due to disposal of undertaking situated at 11/12, Sector E Sanwer Road Industrial Area, Indore M.P. To Formo Plast Private Limited after obtaining the approval of members of the company. <BR> <BR> 10.Due to the revision in Schedule M ( Drug & Cosmetics Rules), the factory is presently undergoing renovation and upgradation work, therefore manufacturing operations were partially disrupted during the year, resulting in a decline in turnover as compared to previous year.2025-04-012026-03-31AuditedStandalone2839520003082300031477500073832000187695000-191900079980001010002720000985200028027900034496000034496000407100025660006637000027859000000027859000-320002782700016273800010152850001.711.71001.711.71Manufacturing Expenses559000Administrative Expenses2549000Selling and Distribution Expenses179000Manufacturing Expenses3261000Administrative Expenses6087000Selling and Distribution Expenses5040006935000000000503000698530003999700002758600006390003262600003091250009506000358628000428481000162738000529050002156430002156430000005945000594500030200000017060400017060400020080400020180004071000206893000212838000428481000Security Deposit503000Advance against material4260000Balance with Government authorities4965000Prepaid Expenses91000Other Assets190000Employee Benefits Payable365000Other Payable1653000Pharma Division11148000Chemical Division64508000Pharma Division189633000Chemical Division943190007565600028395200075656000283952000Pharma Division-3063000Chemical Division7015000Pharma Division23590000Chemical Division9469000395200033059000-736000-1437000468800034496000Pharma Division215844000Chemical Division2126370004284810000428481000Pharma Division127047000Chemical Division857910002128380000212838000101000-65830001072900000-3087000118000000-1392740000460500002720000000232000000000000-310000-3390900058700000066360000-604900000000000133790002005000000000000000000000000113740000000000025487000000101000002538600030711000030711000255300033264000(I)Items that will not be reclassified to Profit or Loss-42000-42000(I)Items that will not be reclassified to Profit or Loss-42000-42000-10000-1000000-32000-32000Biofil Chemicals and Pharmaceuticals Limited******Cyano Pharma Private Limited******Directors and their relatives are directors and Members in the CompanySale of goods or services350000000Approved by Audit Committee and also from members8274000175350000Biofil Chemicals and Pharmaceuticals Limited******Cyano Pharma Private Limited******Directors and their relatives are directors and Members in the CompanyPurchase of goods or services350000000Approved by Audit Committee and also from members4540005750900038662000Biofil Chemicals and Pharmaceuticals Limited******Formo Plast Pvt. Ltd.******Directors and their relatives are directors and Members in the CompanyPurchase of goods or services20000000Approved by Audit Committee and also from members798300006745000Biofil Chemicals and Pharmaceuticals Limited******Ketan Shah******Promoter and Chairman and Managing Director (KMP) of the CompanyRemuneration3000000Approved by Audit Committee and also from members870000116000116000Biofil Chemicals and Pharmaceuticals Limited******Apoorv Jain******Company Secretary and Compliance Officer of the CompanyRemuneration600000Approved by Audit Committee2680004500044000Biofil Chemicals and Pharmaceuticals Limited******Pawan Singh Rajput******Chief Financial Officer of the CompanyRemuneration400000Approved by Audit Committee1500001700018000Biofil Chemicals and Pharmaceuticals Limited******Rohan Shah******Person belong to Promoter Group of the CompanyRemuneration1200000Approved by Audit Committee600000880008800018599000AuditedtrueMAHESHWARI & GUPTAtrue2027-08-31